BECAUSE YOU CAN’T DO THIS TO FL…
THERE’S ZYDELIG®
A first-in-class selective inhibitor of PI3Kδ,
a protein that is expressed in normal and
malignant B cells
ZYDELIG is a PI3Kδ inhibitor indicated for
Relapsed FL after ≥2 systemic therapies
The FL indication was granted accelerated approval based on ORR; improvement
in patient survival or disease-related symptoms has not been established.
FL=follicular B-cell non-Hodgkin lymphoma; ORR=overall response rate;
PI3Kδ=phosphatidylinositol 3-kinase delta.
IMPORTANT SAFETY INFORMATION
BOXED WARNING: FATAL AND SERIOUS TOXICITIES: HEPATIC, SEVERE DIARRHEA,
COLITIS, PNEUMONITIS, AND INTESTINAL PERFORATION
• Fatal and/or serious hepatotoxicity occurred in 14% of ZYDELIG-treated patients. Monitor
hepatic function prior to and during treatment. Interrupt and then reduce or discontinue
ZYDELIG as recommended
• Fatal and/or serious and severe diarrhea or colitis occurred in 14% of ZYDELIG-treated
patients. Monitor for the development of severe diarrhea or colitis. Interrupt and then
reduce or discontinue ZYDELIG as recommended
• Fatal and serious pneumonitis can occur. Monitor for pulmonary
symptoms and bilateral interstitial infiltrates. Interrupt or discontinue
ZYDELIG as recommended
• Fatal and serious intestinal perforation can occur in
ZYDELIG-treated patients. Discontinue ZYDELIG for
intestinal perforation
FL
Please see the following pages for additional
Important Safety Information and Brief Summary of
full Prescribing Information, including BOXED WARNING.
IMAGINE WHAT’S POSSIBLE